DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren Tesh Hotaki, PharmD, BCPS, BCIDP
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Massimo Cristofanilli, MD, FACP
Associate Director of Translational Research and Precision Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Susan Halabi, PhD
Professor of Biostatistics and Bioinformatics
Duke University Medical Center
Durham, North Carolina

Christian S. Hinrichs, MD
Investigator & Lasker Clinical Research Scholar
Experimental Transplantation and Immunology Branch
National Cancer Institute
National Institutes of Health (NIH)
Bethesda, Maryland

Philip Hoffman, MD
(Chairperson)
Professor of Medicine
The University of Chicago
Section of Hematology/Oncology
Department of Medicine
Chicago, Illinois

Heidi D. Klepin, MD, MS
Associate Professor of Internal Medicine
Section of Hematology and Oncology
Wake Forest University Health Sciences
Winston Salem, North Carolina

Anthony D. Sung, MD
(Morning Session Only)
Assistant Professor of Medicine
Duke University School of Medicine
Duke Adult Blood and Marrow Transplant Clinic
Durham, North Carolina

Thomas S. Uldrick, MD, MS
Deputy Head, Global Oncology
Associate Member, Vaccine and Infectious Disease Division
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington
ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Albert L. Kraus, PhD  
(Industry Representative (alternate))  
Global Regulatory Portfolio Lead, Oncology  
Pfizer, Inc.  
Guilford, Connecticut

TEMPORARY MEMBERS (Voting)

Piyush Agarwal, MD  
(Afternoon Session Only)  
Professor of Surgery and Urology  
Director, Bladder Cancer Program  
Fellowship Director, Urologic Oncology  
Comprehensive Cancer Research Center  
University of Chicago  
Chicago, Illinois

Dawn Aldrich, PhD  
(Patient Representative; Morning Session Only)  
New Rochelle, New York

Andrea B. Apolo, MD  
(Afternoon Session Only)  
Clinical Investigator  
Genitourinary Malignancies Branch  
National Cancer Institute, NIH  
Bethesda, Maryland

Randi Hawkins, MD  
(Acting Consumer Representative)  
Department of Internal Medicine  
Internal Medicine/Pulmonary & Critical Care  
Charles R. Drew University of Medicine and Science  
Los Angeles, California

Colette Johnston  
(Patient Representative; Afternoon Session Only)  
Moab, Utah

Matthew H. Kulke, MD  
(Morning Session Only)  
Zoltan Kohn Professor  
Department of Medicine  
Boston University School of Medicine  
Co-Director, Boston University-Boston Medical  
Center Cancer Center  
Boston, Massachusetts

Diane Reidy Lagunes, MD  
(Morning Session Only)  
Medical Oncologist  
Division of Gastrointestinal Oncology  
Memorial Sloan Kettering Cancer Center  
New York, New York

Jonah Murdock, MD, PhD, FACS  
(Afternoon Session Only)  
Chief, Section of Urology  
Washington DC Veterans Affairs Medical Center  
Washington, District of Columbia
TEMPORARY MEMBERS (Voting) (cont.)

**Christian P. Pavlovich, MD**  
*(Afternoon Session Only)*  
Professor of Urology and Oncology  
Director of Urologic Oncology Fellowship  
James Buchanan Brady Urological Institute  
Johns Hopkins University School of Medicine  
Baltimore, Maryland

**Hanna K. Sanoff, MD, MPH**  
*(Morning Session Only)*  
Associate Professor  
Department of Medicine, Division of Hematology/Oncology  
University of North Carolina (UNC)  
Clinic Medical Director, UNC North Carolina Cancer Hospital  
Chapel Hill, North Carolina

**Mohammad Minhaj Siddiqui, MD FACS**  
*(Afternoon Session Only)*  
Director, Urologic Oncology  
Associate Professor of Surgery  
University of Maryland School of Medicine  
Chief of Urology  
Veterans Affairs Maryland Healthcare System  
Baltimore, Maryland

FDA PARTICIPANTS (Non-Voting)

**Richard Pazdur, MD**  
Director, Oncology Center of Excellence (OCE), FDA  
Acting Director, Office of Oncologic Disease (OOD)  
Office of New Drugs (OND), CDER, FDA

**Steven Lemery, MD**  
*(Morning Session Only)*  
Acting Director  
Division of Oncology 3 (DO3)  
OOD, OND, CDER, FDA

**Lola Fashovin-Aje, MD MPH**  
*(Morning Session Only)*  
Acting Deputy Director  
DO3, OOD, OND, CDER, FDA

**Martha Donoghue, MD**  
*(Morning Session Only)*  
Cross-Discipline Team Leader  
Gastrointestinal Cancers Team  
DO3, OOD, OND, CDER, FDA

**Naomi Horiba, MD, MPH**  
*(Morning Session Only)*  
Clinical Reviewer  
Gastrointestinal Cancers Team  
DO3, OOD, OND, CDER, FDA

**Julia Beaver, MD**  
*(Afternoon Session Only)*  
Director  
Division of Oncology 1 (DO1)  
OOD, OND, CDER, FDA
FDA PARTICIPANTS (Non-Voting) (cont.)

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Team/Office</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Daniel Suzman, MD</strong></td>
<td>Acting Clinical Team Leader</td>
<td>Genitourinary Team 2, DO1, OOD, OND, CDER, FDA</td>
</tr>
<tr>
<td><strong>Jamie Brewer, MD</strong></td>
<td>Clinical Reviewer</td>
<td>Genitourinary Team 2, DO1, OOD, OND, CDER, FDA</td>
</tr>
<tr>
<td><strong>Joyce Cheng, PhD</strong></td>
<td>Statistical Reviewer</td>
<td>Division of Biometrics V (DBV), Office of Biostatistics (OB), Office of Translational Science (OTS), CDER, FDA</td>
</tr>
</tbody>
</table>